RxDoctor Payments Data

Francisco Calica, MD

Family Medicine · Beeville, TXNPI 1104813310

Payments from drug & device makers

$1,479in general payments, 2019–2025

Across 83 payments — averaging $17.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$577
  • Lilly USA, LLC$241
  • Sanofi-aventis U.S. LLC$190
  • Novo Nordisk$105
  • GSK$66
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$57
  • plus $243 from 7 others

What the payments were for

  • Food & beverage$1,44698%
  • Education$322%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,479 in reported general payments places this provider in the 65th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$69,829
Medicare patients
101
Services billed
1,098

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin149$129,858
TrulicityDulaglutide105$111,680
FarxigaDapagliflozin Propanediol107$82,450
OzempicSemaglutide73$76,043
MounjaroTirzepatide47$47,336
EliquisApixaban43$41,717
RybelsusSemaglutide40$40,888
XareltoRivaroxaban67$31,172
Trelegy ElliptaFluticasone/Umeclidin/Vilanter40$28,848
Soliqua 100-33Insulin Glargine/Lixisenatide19$24,980
TradjentaLinagliptin30$19,482
SymbicortBudesonide/Formoterol Fumarate80$18,442
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog26$17,565
JanuviaSitagliptin Phosphate20$17,383
EntrestoSacubitril/Valsartan25$15,772

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$241$159,016152 claims
Novo NordiskOzempic, Rybelsus$105$116,930113 claims
AstraZenecaFarxiga, Symbicort$577$100,892187 claims
Johnson & JohnsonXarelto$31$31,17267 claims
GSKTrelegy Ellipta$66$28,84840 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$190$24,98019 claims
MerckJanuvia$53$17,38320 claims
NovartisEntresto$37$15,77225 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Beeville

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →